A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States
- Research Site
-
-
California
-
Concord, California, United States
- Research Site
-
La Jolla, California, United States
- Research Site
-
Los Gatos, California, United States
- Research Site
-
Salinas, California, United States
- Research Site
-
Walnut Creek, California, United States
- Research Site
-
-
Colorado
-
Denver, Colorado, United States
- Research Site
-
-
Connecticut
-
New Britain, Connecticut, United States
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States
- Research Site
-
-
Florida
-
Palm Harbor, Florida, United States
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States
- Research Site
-
-
Kansas
-
Wichita, Kansas, United States
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States
- Research Site
-
-
Michigan
-
Bloomfield Hills, Michigan, United States
- Research Site
-
Detroit, Michigan, United States
- Research Site
-
Grand Rapids, Michigan, United States
- Research Site
-
-
Missouri
-
Chesterfield, Missouri, United States
- Research Site
-
-
Montana
-
Butte, Montana, United States
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States
- Research Site
-
Durham, North Carolina, United States
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Research Site
-
-
Oregon
-
Medford, Oregon, United States
- Research Site
-
Portland, Oregon, United States
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Research Site
-
Tipton, Pennsylvania, United States
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States
- Research Site
-
-
Texas
-
Dallas, Texas, United States
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, United States
- Research Site
-
-
Washington
-
Olympia, Washington, United States
- Research Site
-
Spokane, Washington, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has HbA1c >7.0% and <=10.5%
- Has a body mass index (BMI) >=25 kg/m2 and <=45 kg/m2
- Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start
- If taking oral antidiabetic agents, has been on a stable dose for at least 2 months
Exclusion Criteria:
- Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)
- Has received any investigational drug within 1 month of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Pramlintide
|
Clear, colorless, sterile solution for SC injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes.
Time Frame: 16 Weeks
|
16 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the effects of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes on markers of cardiovascular risk, fasting serum lipids, fasting plasma glucose, waist circumference, and patient-reported outcomes.
Time Frame: 16 Weeks
|
16 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Peyrot M, Rubin RR, Polonsky WH. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther. 2008 Dec;10(6):461-6. doi: 10.1089/dia.2008.0031.
- Wysham C, Lush C, Zhang B, Maier H, Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin. 2008 Jan;24(1):79-85. doi: 10.1185/030079908x253537.
- Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov;30(11):2794-9. doi: 10.2337/dc07-0589. Epub 2007 Aug 13.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 137-156
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.